Thyroid Carcinoma, Anaplastic clinical trials
The registry lists 87 studies for Thyroid Carcinoma, Anaplastic across more than 10 countries. 18 are recruiting or about to start. 44 of them are mainly about Thyroid Carcinoma, Anaplastic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Thyroid Carcinoma, Anaplastic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (6) · Case Comprehensive Cancer Center (3) · Saint Petersburg State University, Russia (3) · Memorial Sloan Kettering Cancer Center (3) · National Taiwan University Hospital (2) · Grupo Espanol de Tumores Neuroendocrinos (2) · Leiden University Medical Center (2)
What is being tested here
Drugs under test in Thyroid Carcinoma, Anaplastic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Zanzalintinib | 2 | 0 | 2 |
| Trametinib | 1 | 1 | 7 |
| Dabrafenib | 1 | 1 | 6 |
| Pembrolizumab | 1 | 0 | 5 |
| Lenvatinib | 1 | 0 | 5 |
| PLX8394 | 1 | 0 | 2 |
| Cemiplimab | 1 | 0 | 1 |
| Enfortumab vedotin | 1 | 0 | 1 |
| Sacituzumab govitecan | 1 | 0 | 1 |
| Sacituzumab tirumotecan | 1 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Antibody-drug conjugates (ADCs) 3 open · Immune checkpoint inhibitors 2 open · Antimitotic agents 8
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 9
- Jan 2027NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) · Leiden University Medical Center
- Apr 2027LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · M.D. Anderson Cancer Center
- Jun 2027Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer · Memorial Sloan Kettering Cancer Center
- Jul 2027Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer · M.D. Anderson Cancer Center
- Aug 2027Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer · M.D. Anderson Cancer Center
- Sep 2027Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer · Memorial Sloan Kettering Cancer Center
- Oct 2027Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Radboud University Medical Center
- Nov 2027[177Lu]Lu-AKIR001 First-in-human Study · Karolinska University Hospital
- Nov 2027Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer · M.D. Anderson Cancer Center
Who these studies take
Of the 13 Thyroid Carcinoma, Anaplastic studies recruiting now, 13 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (23%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (23%) | 3 (23%) |
| 18 | 13 (100%) | 13 (100%) |
| 30 | 13 (100%) | 13 (100%) |
| 40 | 13 (100%) | 13 (100%) |
| 50 | 13 (100%) | 13 (100%) |
| 65 | 13 (100%) | 13 (100%) |
| 75 | 13 (100%) | 13 (100%) |
| 85 | 13 (100%) | 13 (100%) |
Across all 87 studies, recruiting or not: 2% stop at 75 or younger and 1% at 65; 13% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Thyroid Carcinoma, Anaplastic studies take
Of 24 phase 2 interventional studies under Thyroid Carcinoma, Anaplastic, half reached primary completion within 92 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 92 mo46–112 · 24 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- Drug Repurposing in Thyroid Carcinoma: a Feasibility TrialOct 28, 2026NCT07485569
Stopped1
- Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedOct 15, 2026NCT03975231
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 87. Browse all 87 → or search them.
- Drug Repurposing in Thyroid Carcinoma: a Feasibility TrialRecruitingNCT07485569Phase 11 country
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 21 country
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingNCT07470489Phase 21 country
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingNCT07863765Phase 21 country
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingNCT06902376Phase 11 country
- Sacituzumab govitEcan in THYroid CancersRecruitingNCT06235216Phase 21 country
- Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid CancerRecruitingNCT07777536Phase 21 country
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/31 country
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 212 countries
- Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerRecruitingNCT07068542Not applicable1 country
- [177Lu]Lu-AKIR001 First-in-human StudyRecruitingNCT06639191Early Phase 11 country
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/31 country
- Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 21 country
- Taiwanese Anaplastic Thyroid Cancer RegistryNot yet recruitingNCT071382611 country
- Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapyRecruitingNCT06362694Phase 21 country
- NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)RecruitingNCT06079333Phase 21 country
- Study of Clinical Outcomes of Thyroid CancerRecruitingNCT040313391 country
- Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study ExperiencesNot yet recruitingNCT05819593
- Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerCompletedNCT00095693Phase 21 country
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 21 country
- Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 21 country
- Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerActive, not recruitingNCT03085056Early Phase 11 country
- Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedNCT03975231Phase 11 country
- Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 21 country
- CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid TumorsSuspendedNCT07181720Phase 11 country
- A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 11 country
- Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerSuspendedNCT05453799Phase 21 country
- Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 21 country
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingNCT03181100Phase 21 country
- Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerActive, not recruitingNCT04238624Phase 21 country
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 21 country
- Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 21 country
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsSuspendedNCT04418167Phase 11 country
- Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 21 country
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerCompletedNCT04552769Phase 21 country
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/21 country
- Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid CancerActive, not recruitingNCT04420754Phase 11 country
- Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid CancerCompletedNCT02152137Phase 21 country
- Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid CancerCompletedNCT03565536Phase 21 country
- Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWithdrawnNCT04739566Phase 21 country
- Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3CompletedNCT034881341 country
- A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedNCT02244463Phase 1/21 country
- The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationActive, not recruitingNCT05102292Phase 1/21 country
- Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 214 countries
- European Multicenter Study on Surgical Management of Advanced Thyroid CancerStatus unknownNCT057969601 country
- Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/214 countries
- Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid CancerCompletedNCT01236547Phase 21 country
- Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 11 country
- Pembrolizumab in Anaplastic/Undifferentiated Thyroid CancerCompletedNCT02688608Phase 21 country
- Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer PatientsCompletedNCT02862470